• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 9, 2015

View Archived Issues

Inward and upward: Afferent series C adds $55M to 'cough'-ers

Afferent Pharmaceuticals Inc.'s $55 million in series C money gives the firm enough to pay for work that includes the potential phase III trial with AF-219 in idiopathic pulmonary fibrosis (IPF) cough, enabling the firm to "drive this one home ourselves," CEO Kathleen Glaub told BioWorld Today. Read More

House bill would trim FDA appropriations, freeze agency pay rates

Agriculture considerations dominated the July 8 House Appropriations Committee hearing marking up budgets for the FDA and U.S. Department of Agriculture, but those in the life science industries may not have been cheered by the numbers posted by the committee prior to the hearing. Read More

Shenogen seeks to move 'traditional' medicine into cancer mainstream

Jun Bao, senior vice president and chief business officer of Shenogen Pharma Group, begins nearly every presentation about the company with a slide that features strikingly different images. Read More

Post-merger Allergan going full speed ahead with Molecular Partners' Darpin AMD program

Executives of a small biotech must feel some trepidation when forced to watch from the sidelines while their firm's pharma partner – the party often bringing the bulk of the financial backing, as well as the development and commercialization muscle, to the table – becomes itself the subject of an acquisition, a move that could result in reprioritization and termination of a once potentially lucrative collaboration. Read More

Incoming IMI head sizes up the challenge

DUBLIN – Pierre Meulien will wrap up his five-year stint at the helm of Genome Canada at the end of next week, two months before he takes up the post of executive director of the Innovative Medicines Initiative (IMI), the €3.3 billion ($3.7 billion) public-private research partnership between the European Commission and the pharmaceutical industry. Read More

FDA clears Novartis' combo heart failure drug Entresto

It proved a quick nod for Novartis AG's Entresto (sacubitril/valsartan), a combination ACE/neprilysin inhibitor that demonstrated an ability to reduce the rate of cardiovascular death and hospitalization related to heart failure in pivotal trials. Read More

Financings

Clovis Oncology Inc., of Boulder, Colo., said it started an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $275 million. J.P. Morgan Securities LLC is acting as lead book-running manager and representative of the underwriters for the offering. Read More

Stock movers

Read More

Other news to note

Pieris Pharmaceuticals Inc., of Freising, Germany, said it is set to receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Co. Ltd., of Tokyo, and seventh milestone payment overall under their multi-program agreement, inked in 2011. Read More

In the clinic

DBV Technologies SA, of Bagneux, France, said the FDA accepted an investigator-sponsored investigational new drug (IND) application for a phase IIa trial for the treatment of milk-induced eosinophilic esophagitis (EoE) in children using the company's patch therapy Viaskin Milk. Read More

Regulatory front

Sponsors wanting to take advantage of Australia's new annual charge exemption (ACE) scheme have until July 22 to declare that their products had no financial turnover in the past fiscal year. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe